MEDIPOST Inc. Submits IND Amendment With U.S. Food and Drug Administration to Initiate Phase III Trial
Submission marks key step in study of mesenchymal stem cell therapy to treat symptomatic cartilage defects in patients with knee osteoarthritis
CAMBRIDGE, Mass.–(BUSINESS WIRE)–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today that it has filed an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) to support the initiation of a Phase III clinical trial evaluating its investigational cell therapy for knee osteoarthritis.
MEDIPOST’s investigational therapy is an umbilical cord blood-derived allogeneic mesenchymal stem cell therapy designed to treat symptomatic cartilage defects in patients with knee osteoarthritis. Patient enrollment is expected to begin in the first half of 2026.
“Submitting this IND amendment marks an important step toward advancing our U.S. clinical program,” said Edward Ahn, PhD, Chief Executive Officer of MEDIPOST Inc. “Knee osteoarthritis continues to place a significant burden on patients, with limited treatment options that address the underlying disease. Through this study, our focus is on generating rigorous clinical evidence that could support a new treatment approach for people living with this condition.”
Knee osteoarthritis remains a leading cause of pain and loss of mobility, highlighting the need for therapies that go beyond symptom management. MEDIPOST’s planned Phase III study is intended to further evaluate the potential role of regenerative cell therapy in addressing this unmet need.
“Filing an IND amendment reflects our long-term commitment to advancing science that has the potential to make a meaningful difference for patients,” Ahn added.
ABOUT MEDIPOST INC.
MEDIPOST Inc. is a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven and degenerative diseases. The company is advancing a pipeline of regenerative medicine built on its proprietary stem cell technology platform with a focus on scalable, off-the-shelf therapeutic approaches. Learn more at www.medi-post.com.
Contacts
MEDIA CONTACTS
Sam Choinski
Strategic Media Partner
schoinski@longviewstrategies.com
860-301-5058
Barbra Watson
VP of Strategic Communications
bwatson@longviewstrategies.com
781-789-7207
You May Also Like
Americans Fear Losing Human Touch as AI Becomes More Integrated in Life
Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.
BitGo wins BaFIN nod to offer regulated crypto trading in Europe
BitGo’s move creates further competition in a burgeoning European crypto market that is expected to generate $26 billion revenue this year, according to one estimate. BitGo, a digital asset infrastructure company with more than $100 billion in assets under custody, has received an extension of its license from Germany’s Federal Financial Supervisory Authority (BaFin), enabling it to offer crypto services to European investors. The company said its local subsidiary, BitGo Europe, can now provide custody, staking, transfer, and trading services. Institutional clients will also have access to an over-the-counter (OTC) trading desk and multiple liquidity venues.The extension builds on BitGo’s previous Markets-in-Crypto-Assets (MiCA) license, also issued by BaFIN, and adds trading to the existing custody, transfer and staking services. BitGo acquired its initial MiCA license in May 2025, which allowed it to offer certain services to traditional institutions and crypto native companies in the European Union.Read more